Expert answers to common questions about carcinoid and neuroendocrine tumors.

Typical Carcinoid Versus Atypical Carcinoid
Question What is typical versus atypical carcinoid- what is the difference and are they treated differently? Answer Nevena Damjanov, MD, Medical Oncologist at Penn Medicine responds. Typical carcinoid has a "typical" appearance when the pathologist looks at it under the microscope. Clinically, the person with typical carcinoid is likely to

Online Resources for Neuroendocrine and Carcinoid Information
Question What are some online resources for patients? Answer Gloria DiLullo, Nurse Practitioner at Penn Medicine responds. Carcinoid Cancer Foundation: www.carcinoid.org Caring for Carcinoid Foundation: www.caringforcarcinoid.org NET Alliance: www.thenetalliance.com Carcinod Link: www.carcinoid.com North American

Are Carcinoid & Neuroendocrine the Same?
Question Can carcinoid and neuroendocrine tumor be used interchangeably? Or is one not always the other or something? Answer Katie Fanslau, RN, MSN, Nurse in Nuclear Medicine at Penn Medicine responds. There are a several different types of NETs (Neuroendocrine Tumors). So Carcinoid is a type of NET, but not all NETs are carcinoid. Other types

The Caring for Carcinoid Foundation's Plan to Cure Carcinoid
An interview with CFCF's founder and carcinoid survivor, Nancy O'Hagan.

News stories related to carcinoid and neuroendocrine tumors.

Social Network, Early Breast Cancer Prognosis Link Explored
Nov 14, 2012 - For women with early-stage breast cancer, large social networks predict better prognosis, and this association varies based on social support and burden, according to a study published online Nov. 9 in Breast Cancer Research and Treatment.

Negative Pigment Network Able to Distinguish Melanoma
Oct 26, 2012 - Negative pigment network can be used to distinguish melanoma from Spitz nevus and other benign lesions, according to a study published online Oct. 11 in the Journal of the American Academy of Dermatology.

Chemo Combo Promising for Pancreatic Neuroendocrine Tumors
Jul 17, 2012 - The combination of temozolomide and bevacizumab seems to benefit patients with advanced pancreatic neuroendocrine tumors, according to a study published online July 9 in the Journal of Clinical Oncology.

Coverage from professional conferences on research relevant to neuroendocrine tumors.

2005 National Carcinoid-Net Conference
Conference Dates: September 22-24, 2005 Conference Location: Philadelphia, PA Sponsoring Group: Carcinoid Cancer Awareness Network & North American Alliance of Patients with Neuroendocrine Tumors Conference Web Page URL: www.naapnet.org/html/2005conference.html Topics Covered: The Philadelphia conference committee has put together a

Advances in Pituitary Disease: Metabolic, Neuroendocrine and Psychosocial Issues
Date: December 6-8, 2001 Location: Barcelona, Spain Symposium Web Page: www.imedex.com/oncology.htm

Los Angeles Neuroendocrine Tumor Patient Education Seminar
Conference Dates: March 27, 2010, 1-5:30PM Conference Location: Los Angelos Sponsoring Group: Caring for Carcinoid Conference Web Page URL: www.caringforcarcinoid.org/fundraising/laevent.asp Who Should Attend: Patients, Family Members Conference Agenda: On March 27th, come join your fellow neuroendocrine tumor patients for an